Medications

Second Interim Analysis of Clinical Trial Data Showed a 91.4% Efficacy for the Sputnik V Vaccine on Day 28 After the First Dose; Vaccine Efficacy is Over 95% 42 days After the First Dose

The efficacy of the Sputnik V vaccine is 91.4%, based on the second interim analysis of data obtained 28 days after administering the first dose (7 days after the second dose). Calculation was based on the analysis of data on volunteers (n = 18,794) who received both the first and second doses of the Sputnik […]

Medications

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Evidence of Efficacy in First Interim Analysis from Phase 3 Study

NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE) November 9, 2020 Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis Analysis evaluated 94 confirmed cases of COVID-19 in trial participants Study enrolled 43,538 participants, with 42% having diverse backgrounds, […]

Health News

AI imaging analysis prognostic in coronary artery disease

(HealthDay)—Reduced myocardial blood flow (MBF) and myocardial perfusion reserve (MPR) are prognostic for patients with coronary artery disease, according to a study published online Feb. 14 in Circulation. Kristopher D. Knott, M.B.B.S., from University College London, and colleagues examined the prognostic significance of MBF and MPR in 1,049 patients with suspected and known coronary artery […]

Medications

Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers

RESILIENT was a single arm, open label, phase II/III study to test if label agnostic therapy regimens guided by Encyclopedic Tumor Analysis can offer meaningful clinical benefit for patients with relapsed refractory metastatic malignancies. Patients with advanced refractory solid organ malignancies where disease had progressed following 2 lines of systemic treatments were enrolled in the […]